ストックスクリーナーアプリを入手
2.94
2.80%
0.08
プレマーケット:
2.95
0.01
+0.34%
前日終値:
$2.86
開ける：
$2.92
24時間の取引高:
129.25K
Relative Volume:
0.40
時価総額：
$299.21M
収益：
$4.28M
当期純損益:
$-84.59M
株価収益率:
-3.5017
EPS:
-0.8396
ネットキャッシュフロー:
$-87.79M
1週間 パフォーマンス:
-4.85%
1か月 パフォーマンス:
+6.52%
6か月 パフォーマンス:
+1.03%
1年 パフォーマンス:
+48.48%
1日の値動き範囲:
$2.88
$3.08
1週間の範囲:
$2.765
$3.20
52週間の値動き範囲:
$1.4299
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.94 | 299.21M | 4.28M | -84.59M | -87.79M | -0.8396 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | BTIG Research | Buy |
| 2019-02-01 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-04 | 開始されました | UBS | Buy |
| 2018-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-23 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 開始されました | Credit Suisse | Outperform |
| 2016-10-18 | 開始されました | Jefferies | Buy |
| 2016-10-18 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Ac Immune Sa (ACIU) 最新ニュース
AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts - Seeking Alpha
Trading Recap: Will AC Immune SA stock hit new highs in YEAR2026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options - Stock Titan
AC Immune shows first brain images of TDP-43 pathology in trial By Investing.com - Investing.com India
AC Immune shows first brain images of TDP-43 pathology in trial - Investing.com Australia
ACIU Unveils Promising Phase 1 Data for TDP-43 PET Imaging - GuruFocus
AC Immune Presents First In vivo Images of Brain TDP-43 - GlobeNewswire
Aug Volume: Does AC Immune SA outperform in volatile markets2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
AC Immune (ACIU) CFO discloses common shares, RSUs and option grants - Stock Titan
AC Immune (NASDAQ: ACIU) director Monika Buetler details initial share and option holdings - Stock Titan
AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings - Stock Titan
[Form 3] AC Immune SA Initial Statement of Beneficial Ownership - Stock Titan
AC Immune (ACIU) CEO discloses equity and option holdings - Stock Titan
AC Immune (ACIU) director June Carl Howard details share and option stakes - Stock Titan
AC Immune (ACIU) Upgraded to Buy: Here's Why - Yahoo Finance
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? - Yahoo Finance
FY2026 EPS Estimates for AC Immune Lifted by HC Wainwright - MarketBeat
Trend Review: Will AC Immune SA outperform its industry peersWeekly Earnings Recap & Growth Oriented Trading Recommendations - baoquankhu1.vn
ACIU: BTIG Reiterates Buy Rating with $8 Target Price | ACIU Sto - GuruFocus
AC Immune: Advancing Neurology Pipeline and Imminent Alzheimer’s Vaccine Data Support Buy Rating - TipRanks
Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026 - Meyka
AC Immune (ACIU) Loss Of CHF 15.9 Million Tests Bullish Profitability Narratives - simplywall.st
Jefferies reiterates AC Immune stock Buy rating on vaccine data By Investing.com - Investing.com Australia
Jefferies reiterates AC Immune stock Buy rating on vaccine data - Investing.com
AC Immune 2025 Financials: Annual Loss of $85M, Q4 Revenue $423KNews and Statistics - IndexBox
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
ACIU: Positive interim results for ACI-7104 and strategic focus extend cash runway to Q3 2027 - TradingView
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year - TipRanks
AC Immune: Fourth Quarter Financial Results Overview - Bitget
AC Immune: Q4 Earnings Snapshot - Barchart
ACIU: Net loss increased to CHF 70.4 million in 2025 as revenue declined and R&D costs remained high - TradingView
AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones - Stock Titan
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
AC Immune (ACIU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
AC Immune SA expected to post a loss of 17 rappen a shareEarnings Preview - TradingView
Risk Report: What is AC Immune SAs book value per shareJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Aug Big Picture: Should I buy AC Immune SA stock nowJuly 2025 Patterns & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for AC Immune SA stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 - GlobeNewswire
Inside a 2026 push to prevent Parkinson’s at AC Immune’s symposium - Stock Titan
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Will AC Immune SA stock hit new highs in YEAR2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) Begins Phase 1 Trial for New Inflammation Treat - GuruFocus
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor - Investing.com Nigeria
AC Immune Doses First Participant in Phase 1 Trial of NLRP3 Inhibitor ACI-19764 - TipRanks
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor By Investing.com - Investing.com South Africa
AC Immune (NASDAQ: ACIU) begins Phase 1 test of NLRP3 inhibitor ACI-19764 - Stock Titan
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor - The Manila Times
Can AC Immune SA deliver consistent EPS growthMarket Volume Report & Community Verified Trade Signals - mfd.ru
ACIU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug EndMonth: Can AC Immune SA deliver consistent EPS growthTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
Ac Immune Sa (ACIU) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):